Evotec/$EVO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Evotec
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Ticker
$EVO
Sector
Primary listing
Employees
4,740
Headquarters
Website
Evotec Metrics
BasicAdvanced
$1.2B
-
-$1.04
1.15
-
Price and volume
Market cap
$1.2B
Beta
1.15
52-week high
$5.48
52-week low
$2.84
Average daily volume
52K
Financial strength
Current ratio
2.118
Quick ratio
1.148
Long term debt to equity
48.46
Total debt to equity
60.567
Interest coverage (TTM)
-5.37%
Profitability
EBITDA (TTM)
0.015
Gross margin (TTM)
10.82%
Net profit margin (TTM)
-21.02%
Operating margin (TTM)
-10.72%
Effective tax rate (TTM)
-20.35%
Revenue per employee (TTM)
$184,580
Management effectiveness
Return on assets (TTM)
-2.69%
Return on equity (TTM)
-17.98%
Valuation
Price to revenue (TTM)
0.672
Price to book
1.29
Price to tangible book (TTM)
2.07
Price to free cash flow (TTM)
-5.603
Free cash flow yield (TTM)
-17.85%
Free cash flow per share (TTM)
-0.59
Growth
Revenue change (TTM)
-2.67%
Earnings per share change (TTM)
-6.94%
3-year revenue growth (CAGR)
2.72%
10-year revenue growth (CAGR)
20.34%
3-year earnings per share growth (CAGR)
-4.21%
10-year earnings per share growth (CAGR)
26.05%
What the Analysts think about Evotec
Analyst ratings (Buy, Hold, Sell) for Evotec stock.
Evotec Financial Performance
Revenues and expenses
Evotec Earnings Performance
Company profitability
Evotec News
AllArticlesVideos
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
Accesswire2 days ago
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Accesswire3 days ago
Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025
Accesswire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evotec stock?
Evotec (EVO) has a market cap of $1.2B as of November 07, 2025.
What is the P/E ratio for Evotec stock?
The price to earnings (P/E) ratio for Evotec (EVO) stock is 0 as of November 07, 2025.
Does Evotec stock pay dividends?
No, Evotec (EVO) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next Evotec dividend payment date?
Evotec (EVO) stock does not pay dividends to its shareholders.
What is the beta indicator for Evotec?
Evotec (EVO) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.